N-(4-Methyl-benzyl)-N-phenyl-isonicotinamide | 951027-88-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-Methyl-benzyl)-N-phenyl-isonicotinamide
• 英文别名: N-[(4-methylphenyl)methyl]-N-phenylpyridine-4-carboxamide
• CAS: 951027-88-6
• 化学式: C₂₀H₁₈N₂O
• 分子量: 302.376
• InChiKey: PHEUWWXHEREOIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS
  申请人：Arista Luca

  公开号：US20100261758A1

  公开（公告）日：2010-10-14

  Compounds of Formula (I) wherein R 1 is aryl, cyclohexyl or heterocyclyl, or (C 1-4 )alkyl substituted by aryl, cyclohexyl or heterocyclyl, R 2 is defined heterocyclyl, R 3 is alkyl, aryl, cyclohexyl or heterocyclyl, or (C 1-4 )alkyl substituted by aryl, cyclohexyl or heterocyclyl, R 4 is H or alkyl, or R 3 and R 4 together with the carbon atom to which they are attached are cycloalkyl fused with aryl, and their use as pharmaceuticals.

  化合物的公式（I），其中R1是芳基，环己基或杂环基，或被芳基，环己基或杂环基取代的（C1-4）烷基，R2是定义的杂环基，R3是烷基，芳基，环己基或杂环基，或被芳基，环己基或杂环基取代的（C1-4）烷基，R4是H或烷基，或R3和R4与它们所连接的碳原子一起是环状烷基与芳基融合，以及它们作为药物的用途。
• 1,3,4-OXADIAZOLE AMIDE DERIVATIVE COMPOUND AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
  申请人：Chong Kun Dang Pharmaceutical Corp.

  公开号：EP3330259A1

  公开（公告）日：2018-06-06

  The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.

  本发明涉及具有组蛋白去乙酰化酶6（HDAC6）抑制活性的新型化合物、其立体异构体或其药学上可接受的盐、其用于制备治疗药物的用途、含有其的药物组合物、使用该组合物治疗疾病的方法以及制备该新型化合物的方法。根据本发明的新型化合物、其立体异构体或其药学上可接受的盐具有组蛋白去乙酰化酶6（HDAC6）抑制活性，可有效预防或治疗HDAC6介导的疾病，包括感染性疾病；肿瘤；内分泌、营养和代谢性疾病；精神和行为障碍；神经系统疾病；眼睛和附件疾病；心血管疾病；呼吸系统疾病；消化系统疾病；皮肤和皮下组织疾病；肌肉骨骼系统和结缔组织疾病；或先天性畸形、变形和染色体异常。
• AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREAMENT OF G PROTEIN RELATED DISEASES
  申请人：NOVARTIS AG

  公开号：EP2001851A2

  公开（公告）日：2008-12-17
• [EN] HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS<br/>[FR] AMIDES HETEROCYCLIQUES DESTINES A UNE UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：NOVARTIS AG

  公开号：WO2007110237A2

  公开（公告）日：2007-10-04

  [EN] Compounds of Formula (I) wherein R₁ is aryl, cyclohexyl or heterocyclyl, or (C_1-4)alkyl substituted by aryl, cyclohexyl or heterocyclyl, R₂ is defined heterocyclyl, R₃ is alkyl, aryl, cyclohexyl or heterocyclyl, or (C_1-4)alkyl substituted by aryl, cyclohexyl or heterocyclyl, R₄ is H or alkyl, or R₃ and R₄ together with the carbon atom to which they are attached are cycloalkyl fused with aryl, and their use as pharmaceuticals.
  [FR] L'invention concerne des composés de formule (I), dans laquelle R₁ représente un aryle, un cyclohexyle ou un hétérocyclyle ou un (C_1-4)alkyle substitué par un aryle, un cyclohexyle ou un hétérocyclyle, R₂ représente un hétérocyclyle, R₃ représente un alkyle, un aryle, un cyclohexyle ou un hétérocyclyle ou un (C_1-4)alkyle substitué par un aryle, un cyclohexyle ou un hétérocyclyle, R₄ représente H ou un alkyle, ou bien R₃ et R₄ forment ensemble avec l'atome de carbone auquel ils sont attachés un cycloalkyle condensé avec un aryle. L'invention concerne également leur utilisation en tant que produits pharmaceutiques.